A Phase IIa, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of PBF-680 in Patients With Moderate to Severe COPD on Top of the Standard Medication
Latest Information Update: 23 Apr 2024
Price :
$35 *
At a glance
- Drugs PBF 680 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms Respire
- Sponsors Palobiofarma
- 18 Apr 2024 Status changed from active, no longer recruiting to completed.
- 08 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Aug 2024.
- 08 Feb 2024 Planned primary completion date changed from 1 Dec 2023 to 1 May 2024.